Vascular brachytherapy for hemodialysis vascular access dysfunction: Exploring an unmet clinical need

Journal of Invasive Cardiology

Volumn 15, Issue SUPPL. A, 2003, Pages

  Roy Chaudhury, Prabir ^a,b   Duncan, Heather ^a   Barrett, William ^a   Elson, Howard ^a   Narayana, Ashwath ^a   Foley, Jeri ^a   Misra, Sanjay ^a   Lynch, Pia Mikkelsen ^a   Zuckerman, Darryl ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Endovascular radiation therapy; Hemodialysis vascular access dysfunction; Smooth muscle cell proliferation; Venous neointimal hyperplasia; Venous stenosis

Indexed keywords

POLITEF;

BLOOD VESSEL INJURY; BRACHYTHERAPY; CLINICAL TRIAL; GRAFT DYSFUNCTION; HEMODIALYSIS; HEMODIALYSIS VASCULAR ACCESS DYSFUNCTION; HUMAN; MORBIDITY; RESTENOSIS; REVIEW; STENOSIS; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE; VASCULAR ACCESS; CHRONIC KIDNEY FAILURE; HYPERPLASIA; RENAL REPLACEMENT THERAPY; UNITED STATES; VASCULAR DISEASE; VEIN THROMBOSIS;

BRACHYTHERAPY; HUMANS; HYPERPLASIA; KIDNEY FAILURE, CHRONIC; MORBIDITY; POLYTETRAFLUOROETHYLENE; RENAL DIALYSIS; UNITED STATES; VASCULAR DISEASES; VENOUS THROMBOSIS;

EID: 0037837615     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. USRDS. United States Renal Data System annual report. Minneapolis, Minnesota: United States Renal Data System, 2001.
2. Feldman HI KS, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol 1996;7:523-535.
3. Schwab SJ, Harrington JT, Singh A, et al. Vascular access for hemodialysis (clinical conference). Kidney Int 1999;55:2078-2090.
4. Beathard C. The treatment of vascular access dysfunction: A nephrologists view and experience. ARRT 1994;1:131-147.
5. Schwab SJ. DOQI Clinical Practice Guidelines. New York: National Kidney Foundation, 1997.
6. Himmelfarb J, Saad T. Hemodialysis vascular access: Emerging concepts. Curr Opin Neplirol Hypertens 1996;5:485-491.
7. Blankestijn PJ, Bosman PJ, Boereboom FT. Hemodialysis access without thrombosis: Is it possible? (editorial). Nephrol Dial Transplant 1996;11:2394-2397.
8. Himmelfarb J, Ikizler TA, Hakim RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney International 2002;62:1524-1538.
9. Keren G. Compensatory enlargement, remodeling, and restenosis. Adv Exp Med Biol 1997;430:187-196.
10. Nakamura Y, Zhao H, Yutani C, et al. Morphometric and histologic assessment of remodeling associated with restenosis after percutaneous transluminal coronary angioplasty. Cardiology 1998;90:115-121.
11. Libby P, Tanaka H. The molecular bases of restenosis. Prog Cardiovasc Dis 1997;40:97-106.
12. Schwartz RS, Topol EJ, Serruys PW, et al. Artery size, neointima, and remodeling: Time for some standards. J Am Coll Cardiol 1998;32:2087-2094.
13. Chen C, Ku DN, Kikeri D, Lumsden AB. Tenascin: A potential role in human arteriovenous PTFE graft failure. J Surg Res 1996;60:409-416.
14. Rekhter M, Nicholls S, Ferguson M, Gordon D. Cell proliferation in human arteriovenous fistulas used for hemodialysis. Arterioscler Thromb 1993;13:609-617.
15. Swedberg SH, Brown BG, Sigley R, et al. Intimai fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation 1989;80:1726-1736.
16. Roy-Chaudhury P, Miller MA, Reaves A, et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney International 2001;59:2325-2334.
17. Fareh J, Martel R, Kermani P, Leclerc G. Cellular effects of beta-particle delivery on vascular smooth muscle cells and endothelial cells: A dose-response study. Circulation 1999;99:1477-1484.
18. Haimovitz-Friedman A. Signaling in the radiation response of endothelial cells. In: Rubin DB (ed). The radiation biology of the vascular endothelium. Boston: CRC Press, 1998: pp. 101-127.
19. Rubin P, Williams JP, Riggs PN, et al. Cellular and molecular mechanisms of radiation inhibition of restenosis. Part I: Role of the macrophage and platelet-derived growth factor. Int J Radiat Oncol Biol Phys 1998;40:929-941.
20. Wiedermann JG, Marboe C, Amols H, et al. Intracoronary irradiation markedly reduces neointimal proliferation after balloon angioplasty in swine: Persistent benefit at 6-month follow-up. J Am Coll Cardiol 1995;25:1451-1456.
21. Weinberger J, Ennis RD, Schwanz A, et al. Intracoronary radiation: Dose response for the prevention of restenosis in swine. Int J Radiation Oncology Biol Phys 1996;36:767-775.
22. Kelly B, Heffelfinger S, Miller MA, et al. External beam radiation attenuates venous neointimal hyperplasia in a pig model of arteriovenous PTFE graft stenosis. Int J Radiation Oncology, Biology and Physics 2002;54:263-269.
23. Trerotola SO, Cannody TJ, Timmerman RD, et al. Brachytherapy for the prevention of stenosis in a canine hemodialysis graft model: Preliminary observations. Radiology 1999;212:748-754.
24. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250-256.
25. Verin V, Popowski Y, de Bruyne B, et al. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study group. N Engl J Med 2001;344:243-249.
26. Raizner AE, Oesterle SN, Waksman R, et al. Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 2000;102:951-958.
27. Waksman R, Wea R. Intravascular gamma radiation for in-stent restenosis in saphenous vein bypass grafts. N Engl J Med 2002;346:1194-1199.
28. Parikh S, Rogers D, Charytan C, et al. External beam radiation therapy to prevent postangioplasty dialysis access restenosis: A feasibility study. Cardiovasc Radiation Med 1999;1:36-41.
29. Cohen GS, Ringold MA. External beam irradiation as an adjunctive treatment in failing dialysis shunts. J Vasc & Intervent Radiology 2000;11:321-326.
30. Sapirstein W, Zuckerman B, Dillard J. FDA approval of coronaryartery brachytherapy. N Engl J Med 2001;344:297-299.
31. III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: Update 2000. Am J Kidney Dis 2001;37(Suppl 1):S137-S181.